The Current Status of Allogenic Islet Cell Transplantation
Cells · 10.10.2023 · 12 (20) · 2423
DOI: 10.3390/cells12202423 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 10.10.2023. Verfasst von Zofia Czarnecka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, Canada. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Islets of Langerhans, Insulin-Secreting Cells. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type 1 Diabetes (T1D) is an autoimmune destruction of pancreatic beta cells. The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. In 2022, the 20-year follow-up findings of islet cell transplantation demonstrated the long-term safety of islet cell transplantation despite chronic immunosuppression. The Edmonton Protocol, however, remains limited by two obstacles: scarce organ donor availability and risks associated with chronic immunosuppression. To overcome these challenges, the search has begun for an alternative cell source. In 2006, pluripotency genomic factors, coined “Yamanaka Factors,” were discovered, which reprogram mature somatic cells back to their embryonic, pluripotent form (iPSC). iPSCs can then be differentiated into specialized cell types, including islet cells. This discovery has opened a gateway to a personalized medicine approach to treating diabetes, circumventing the issues of donor supply and immunosuppression. In this review, we present a brief history of allogenic islet cell transplantation from the early days of pancreatic remnant transplantation to present work on encapsulating stem cell-derived cells. We review data on long-term outcomes and the ongoing challenges of allogenic islet cell and stem cell-derived islet cell transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, Canada.
ORCID-Profile: Nidheesh Dadheech, Haide Razavy, A M James Shapiro
Zitieren
APA
Czarnecka, Z., Dadheech, N., Razavy, H., Pawlick, R., & Shapiro, A. M. J. (2023). The Current Status of Allogenic Islet Cell Transplantation. Cells, 12(20), 2423. https://doi.org/10.3390/cells12202423
Vancouver
Czarnecka Z, Dadheech N, Razavy H, Pawlick R, Shapiro AMJ. The Current Status of Allogenic Islet Cell Transplantation. Cells. 2023;12(20):2423. doi:10.3390/cells12202423
BibTeX
@article{Czarnecka2023,
author = {Czarnecka, Zofia and Dadheech, Nidheesh and Razavy, Haide and Pawlick, Rena and Shapiro, A M James},
title = {The Current Status of Allogenic Islet Cell Transplantation},
journal = {Cells},
year = {2023},
volume = {12},
number = {20},
pages = {2423},
doi = {10.3390/cells12202423}
}
EUVIMED